RT Journal Article
SR Electronic
T1 Pembrolizumab and Radiotherapy for Platinum-refractory Recurrent Uterine Carcinosarcoma With an Abscopal Effect: A Case Report
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4131
OP 4135
DO 10.21873/anticanres.14412
VO 40
IS 7
A1 YANO, MITSUTAKE
A1 ASO, SAKI
A1 SATO, MIHO
A1 AOYAGI, YOKO
A1 MATSUMOTO, HARUNOBU
A1 NASU, KAEI
YR 2020
UL http://ar.iiarjournals.org/content/40/7/4131.abstract
AB Background: Immune responses due to radiotherapy and immune checkpoint inhibitors potentially have synergistic effects. Case Report: Here, we report a 65-year-old Japanese woman presenting with high-grade endometrial cancer. She was diagnosed with carcinosarcoma, stage IB. A month post-surgery, lung, and mediastinal lymph node metastasis/recurrence was detected. Progressive disease (with high microsatellite instability) with local recurrence and bone metastasis was detected after six chemotherapy cycles with paclitaxel and carboplatin. After combination therapy with pembrolizumab (2 mg/kg, tri-weekly, 10 cycles) and pelvic radiotherapy (30 Gy/10 fractions), enhanced computed tomography revealed a complete response. The patient survived for 14 months with the residual tumour post-relapse. This is the first case of a complete response of recurrent endometrial carcinosarcoma upon combinatorial pembrolizumab and radiotherapy. Conclusion: Combinatorial immune checkpoint inhibitors and local radiotherapy cause the abscopal effect and may be a promising treatment strategy for advanced or recurrent carcinosarcomas refractory to traditional chemotherapy.